S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
ASX:RNO

Rhinomed Limited (RNO.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.07
MA: A$0.07
A$0.07
52-Week Range N/A
Volume452,773 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; and Pronto for nasal congestion and sleep disturbance issues. It also engages in developing applications for the delivery of medical cannabis and conditions, including anxiety, pain, allergies, nausea, anxiety, and coughs and colds; and nasal swab to test the presence of upper respiratory tract diseases, including influenza, and coronavirus strains. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-84160900
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.24 million
Book ValueA$0.04 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive RNO News and Ratings via Email

Sign-up to receive the latest news and ratings for RNO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rhinomed Limited (RNO.AX) (ASX:RNO) Frequently Asked Questions

What stocks does MarketBeat like better than Rhinomed Limited (RNO.AX)?

Wall Street analysts have given Rhinomed Limited (RNO.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rhinomed Limited (RNO.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Rhinomed Limited (RNO.AX)'s earnings last quarter?

Rhinomed Limited (RNO.AX) (ASX:RNO) announced its quarterly earnings data on Thursday, February, 28th. The company reported ($0.02) earnings per share for the quarter.
View Rhinomed Limited (RNO.AX)'s earnings history
.

Who are some of Rhinomed Limited (RNO.AX)'s key competitors?

Who are Rhinomed Limited (RNO.AX)'s key executives?

Rhinomed Limited (RNO.AX)'s management team includes the following people:
  • Mr. Michael Johnson, CEO, MD & Exec. Director
  • Mr. Sean Slattery, CFO & Company Sec.

What is Rhinomed Limited (RNO.AX)'s stock symbol?

Rhinomed Limited (RNO.AX) trades on the ASX under the ticker symbol "RNO."

How big of a company is Rhinomed Limited (RNO.AX)?

Rhinomed Limited (RNO.AX) has a market capitalization of $0.00 and generates $4.24 million in revenue each year.

What is Rhinomed Limited (RNO.AX)'s official website?

The official website for Rhinomed Limited (RNO.AX) is www.rhinomed.com.au.

How can I contact Rhinomed Limited (RNO.AX)?

Rhinomed Limited (RNO.AX)'s mailing address is 97 Green St, RICHMOND, VIC 3121, Australia. The company can be reached via phone at +61-3-84160900.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.